Administration of liposome-and polymer-based clinical nanomedicines, as well as many other proposed multifunctional nanoparticles, often triggers hypersensitivity reactions without the involvement of IgE. These anaphylactic reactions are believed to be secondary to activation of the complement system, giving rise to the release of anaphylatoxins C3a and C5a that initiate a wide array of responses through their effect on mast cells, polymorphonuclear cells, platelets and monocytes. Additionally, the terminal complement C5b-9 complex induces platelet activation, thereby enhancing their procoagulant activity, and has the capacity to elicit non-lytic stimulatory responses from vascular endothelial cells. Here we discuss the molecular basis of complement activation by liposomes, including poly(ethylene glycol) coated vesicles, and other related lipid-based and phospholipidpoly(ethylene glycol) conjugate stabilized entities. We have further considered the role of these complement activating entities in experimental oncology since intra-tumoural complement activation is suggested to induce tumour growth and progression.
INTRODUCTION
Advances in design and engineering of nanoscale delivery systems with distinct physical and biochemical properties are beginning to positively impact clinical practice at many levels.
1 These include disease diagnosis and imaging, detection of molecular changes responsible for disease pathogenesis and site-specific drug delivery combined with triggered-release mechanisms. Among such entities, liposomes are at the forefront of nanomedicine * Author to whom correspondence should be addressed. development; several clinically approved vesicular formulations for combating fungal infections and cancer are currently in the market. 2 However, a common, yet poorly understood, immune side effect of liposomal drug therapy (as well as other lipid-based systems) is IgE-independent infusion-related hypersensitivity reaction, where haemodynamic, respiratory, cutaneous and subjective manifestations include hypotension or hypertension, dyspnea, flushing, rash, and feeling of choking. 3 Such reactions (or pseudoallergy) develop in 2-45% of patients within minutes of liposome infusion and are strongly believed to arise through rapid production of anaphylatoxins C3a and C5a via complement activation. 3 4 These pleiotropic inflammatory mediators exert damage through their effects on monocytes/macrophages, polymorphonuclear cells (PMNs), platelets and mast cells. 4 Here we briefly evaluate the molecular basis of complement activation by liposomes, including poly(ethylene glycol) (PEG) coated vesicles and other related lipid/phospholipid-stabilized nanosystems. Furthermore, in most pathophysiological scenarios local activation of both the complement and coagulation cascades Thomas L. Andresen was born in Copenhagen, Denmark. He received his Ph.D. in chemistry form the Technical University of Denmark. After working as director of formulation development in the biotech industry he established his own research group at the Department of Micro-and Nanotechnology, Technical University of Denmark in 2007, focusing on advanced drug delivery research and membrane biophysics.
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THE COMPLEMENT SYSTEM
The complement system, consisting of approximately 35 soluble plasma and cell-surface bound proteins (including regulators), is perhaps the most ancient defence system of the body, which provides an essential link between innate and adaptive immunity. 7 8 Complement contributes to the destruction and removal of microorganisms and other foreign particles (e.g., synthetic nanoparticles) as well as apoptotic and necrotic cells, either by direct lysis (through the formation of the membrane-attack complex) or by mediating leukocyte functions in inflammation and innate immunity. [7] [8] [9] The role of complement in cell differentiation, which includes tissue regeneration, neuron development and reproduction has also been reported. The central step in complement activation cascade is the enzymatic cleavage of C3 into C3b and C3a, which can be initiated by three different pathways the classical, lectin and alternative pathway (Fig. 1) . 7 12 Similarly, patients with rheumatoid arthritis produce increased levels of a certain glycoform of IgG (IgG-G0) that lacks the terminal galactose moieties on the N-terminal glycan chains that bind MBL; 13 there also exists glycoforms of IgM with high affinity for MBL.
14 Spontaneous hydrolysis of the internal thioester bond within C3 in the fluid phase initiates activation of the alternative pathway (AP), which through the binding and subsequent activation of factor B lead to assembly of the fluid phase C3 convertase C3bBb. 7 8 15 Furthermore, foreign surface rich in either hydroxyl or amino groups (and to some extent carboxylic groups) can directly trigger AP turnover. 16 The AP, however, serves as a unique up-regulating mechanism that establishes a highly efficient amplification loop for C3 conversion (C3-feedback) in any type of complement activation. IgG antibodies readily bind nascent C3b; for example C3b-C3b-IgG complexes act as a major substrate of C3bBb and amplifies AP turnover on the surface of sensitized targets. 17 Indeed, C3b covalently bound to IgG is less susceptible to inactivation by complement regulators (factors H and I) than free C3b or C3b bound to non-IgG acceptors.
There are additional pathways that cleave C3; these include the C2-bypass pathway where MBL/MASP-2 is believed to directly attack C3 without formation of the corresponding C3 convertase, 18 and the extrinsic protease pathway involving kallikrein and thrombin capable of cleaving both C3 and C5. 5 Deposition of C3b on target surfaces generates two cellular responses. The first is priming of foreign surfaces for phagocytic clearance where C3b and its proteolytic fragments iC3b and C3dg are recognized by the macrophage complement receptors (CRs); these include CR1, CR3, CR4 and CRIg. 3 19 The second is up-regulation of B-cell response via CR2 and through the co-stimulatory and B-cell receptor complexes. 20 C3b further participates in the formation of the C5 convertases (C4bC2aC3b of CP and LP, C3bC3bBb of AP); these proteases cleave C5 to C5a and C5b, with eventual assembly of the terminal C5b-9 complement membrane-attack complex that following incorporation into membrane of pathogens or cells (or liposomes), induces their lysis. 7 8 
COMPLEMENT-MEDIATED DAMAGE
Inappropriate activation of the complement system may induce severe tissue damage and initiate adverse reactions in sensitive individuals. Tissue injury is mediated directly by C5b-9, and indirectly by anaphylatoxins C3a and C5a through their effect on a plethora of blood cells. 16 For example, apart from mast cell and basophil activation, leading to the release of thromboxane A2 and other pro-inflammatory mediators, C3a can further activate platelets, enhancing their aggregation and adhesion.
C5a is 100-fold more potent than C3a, but can further enhance blood thrombogenicity through upregulation of tissue factor and plasminogen activator inhibitor-1 expression on various cell types.
5 C5b-9 complexes also have the capacity to elicit non-lytic stimulatory responses from vascular endothelial cells and modulate endothelial regulation of haemostasis and inflammatory cell recruitment. 21 Other fragments such as iC3b can induce up-regulation of certain adhesion molecules on neutrophils and endothelial cells. 5 16 
COMPLEMENT ACTIVATION BY LIPOSOMES AND RELATED SYSTEMS
The mechanisms by which liposomes activate complement are still poorly understood and the majority of information has been obtained from experiments involving diluted sera and non-physiological conditions. Complement activation by liposomes depends on a number of physicochemical factors that include lipid type and membrane composition, the extent of membrane fluidity/rigidity and defects, vesicular morphology and size, and these have been reviewed recently. 22 Generally, liposomal activation of the CP proceeds following the binding of naturally occurring IgG and IgM antibodies to phospholipid head-groups and the hydroxyl moiety of the cholesterol, however, the titer and specificities of such antibodies show substantial interindividual variation. [22] [23] [24] [25] The extent of activation could also depend on antibody packing density and transient conformational changes. Additional epitopes for the binding of such antibodies may further become available through adsorption of other plasma proteins, such as apolipoprotein H. 26 Liposomes, can further trigger CP activation either through direct C1q binding; a feature prominent with vesicles exhibiting high surface density of anionic charge, 27 or through CRP binding. 28 29 However, depending on vesicular lipid composition and membrane curvature C3b binding may physically shield the underlying C1q, antibody and CRP molecules as this may block available acceptor sites for C4b binding and the assembly of the C3 convertases.
In contrast to CP mode of activation, liposomemediated triggering of LP has not received much attention. MBL binds phosphatidylinositol-containing liposomal membranes, 30 and mannose-or other carbohydratedecorated liposomes, and depending on surface sugar density, will likely trigger complement activation through this pathway. Depending on serum source, non-specific adsorption of abnormally glycosylated proteins, such as apo-lipoprotein variants and IgG-G0 may further aid LP activation.
Some liposomes can directly accelerate alternative pathway turnover but the mechanisms are rather obscure. 22 25 Liposome-mediated AP activation may proceed through non-specific binding of C3b-C3b-IgG or intact C3. The binding of the latter may be associated with a conformation change mimicking that of bound C3b, giving rise to formation of the C3bBb convertase. Additionally, other liposome adsorbed proteins (such as albumin) may expose sites for the binding of nascent C3b, thus accelerating AP turnover. Liposomal surface modifications with methoxyPEG (mPEG) confer longevity to vesicles in the systemic circulation. 19 Surface PEGylation has been repeatedly argued to dramatically suppress protein adsorption and opsonization events, including complement activation and fixation, but the latter view is often based on experiments with diluted sera. Contrary to such views recent experiments in undiluted human sera has conclusively demonstrated that long-circulating PEGylated liposomes can activate human complement through both CP and AP. 9 31 Although the extent of complement activation by PEGylated liposomes may depend on the titer of antiPEG antibodies (indeed, IgG and IgM antibodies against PEGs are found in 22-25% of the healthy blood donor population), 32 the anionic charge localized on the phosphate-oxygen of mPEG-phospholipid conjugate was identified as the key driver in initiating complement activation (but concomitantly with the phospholipid headgroups of liposomal bilayer) through C1q-mediated CP and in the absence of anti-PEG antibodies. 31 Following methylation of the phosphate-oxygen moiety of the conjugate, and hence charge removal, complement activation disappeared both in vitro (in human sera) and in vivo experiments. 31 As a result of these observations, the blood longevity of PEGylated liposomes has now been suggested to strongly arise from the steric hinderance of the projected mPEG chains, thus minimizing the binding of complement-fixed vesicles to CRs on hepatic and splenic phagocytes. 31 33 mPEG-phospholipid conjugates are capable of forming micellar structures of approximately 20 nm in size, with exceptionally low critical micelle concentration, that remain stable following dilution in the blood. In contrast to PEGylated liposomes, such micellar constructs do not activate the complement system and this makes them an attractive alternative for drug solubilization and cancer drug delivery. 31 The inability of these micelles to activate complement may partly be due to their very small size, which in combination with surface dynamic events could restrict surface assembly of C4b2a (which is of similar size range to these micelles) as well as accelerating formation of the fluid phase AP convertase.
Carbon nanotubes are receiving attention among chemists and material scientists as entities for intravenous drug delivery, although being non-biodegradable and despite the fact that it takes prolonged periods of time before they are removed from the body, predominantly through biliary excretion. 34 Non-functionalized high pressure carbon monoxide single-walled carbon nanotubes (SWNTs) and double-walled carbon nanotubes (DWNTs), however, are potent activators of the complement system. 35 SWNTs activate CP exclusively via C1q adsorption, whereas DWNTs can activate both CP (C1q-mediated) and AP. Remarkably, mPEG-phospholipid stabilized SWNTs are also capable of activating complement but activation proceeds exclusively through LP in a MASP-2-dependent manner. 36 The molecular basis of SWNT-mediated LP activation remains unknown but it is very likely that adsorption of some glycosylated plasma proteins such as apo-lipoproteins or their variants (or acetylated compounds) to PEGylated SWNTs could trigger MBL/ficolin binding (Fig. 2) . Much attention has also been focused on pro-inflammatory reactions following environmental exposure to carbon nanotubes. 37 38 Although not proven, these reactions may have routes in complement activation. For instance, in the mucosal system, a major factor of defence is IgA where it may bind to carbon nanotubes and activate complement through both LP and AP. Similarly, collectins, such as lung surfactant proteins A and D, play an important role in innate immunity by protecting the lung from microbial infection and injury, but they can also promote chronic inflammation, partly through local complement activation and ultimately damage the lung. Indeed, lung collectins, which are of similar structure to C1q, have been shown to selectively bind carbon nanotubes in a calcium-dependent fashion, where the presence of carboxylic, aldehyde and ketone group on nanotubes have been suggested to provide coordination sites for the calcium ions bound to lung surfactant proteins. 38 Solid lipid nanoparticles (SLNs) are also receiving increasing attention for site-specific drug delivery. 39 Some studies have concentrated on the pattern of protein adsorption from citrated human plasma (this blocks complement activation primarily through calcium-sensitive pathways) on these particles but detailed studies on complement activation by SLNs are scant. 40 Surface modification of SLNs have also been achieved by non-ionic surfactants of poloxamer and poloxamine series, 40 but recent studies have confirmed the complement activating nature of such surfactants in sub-micellar, micellar and surface-adsorbed forms where activation through both calcium-sensitive pathways and AP prevails. 9 31 41 These nonionic surfactants can further modulate macrophage functions. 42 43 Interestingly, there are structural similarities between the terminal poly(ethylene oxide) moieties of these block co-polymers and a region of D-mannose that could aid complement activation through LP. However, one remarkable feature arising from protein binding studies is surface enrichment of SLNs with a wide array of apolipoproteins; 40 the same feature is also true with PEGylated liposomes. 44 Adsorption of apo-lipoproteins A-I and A-II to such entities is rather intriguing as these apolipoproteins are inhibitors of C9 polymerization that can minimize generation of C5b-9 complexes (but not anaphylatoxins) and hence their deposition on vascular endothelial cells. 45 In accordance with the latter suggestion, our preliminary observations have confirmed that cholesterolrich (45 mol% cholesterol) liposome-induced rises of S-protein-bound form of C5b-9 terminal complex (SC5b-9) can be significantly suppressed when serum HDL cholesterol levels are increased by 30%. 44 While intravenous injection of cholesterol-rich liposomes into pigs was associated with an immediate circulatory collapse, the drop in systemic arterial pressure following injection of liposomes preincubated with human HDL was slow and extended. 46 Therefore, surface-associated lipoprotein particles (or apo-lipoproteins) seem to lessen liposome-induced adverse haemodynamic changes, possibly as a consequence of suppressed C5b-9 assembly in vivo.
Chemically-modified castor oil is widely used in pharmaceutical preparations. The non-ionic solubilizer Cremophor EL (CrEL) is derived by reacting ethylene oxide with castor oil and at concentrations above 60 g/ml is capable of forming micelles of 8-25 nm in size; this allows rapid solubilization of hydrophobic/amphipathic drugs such as paclitaxel, teniposide and cyclosporine. 47 The occurrence of hypersensitivity reactions to CrELbased pharmaceuticals is very common and is extensively documented in the case of Taxol ® (paclitaxel solubilized in CrEL/ethanol). 4 48 Indeed, reactions to Taxol ® infusion occur in about 2-7% of cancer patients despite premedication with high-dose dexamethasone, antihistamines and H2-antagonists, and are severe and life-threatening in some 2% of the recipients. These reactions are also believed to be secondary to complement activation. 47 In serum CrEL can substantially decrease the electrophoretic mobility of both HDL and LDL, resulting in de novo formation of larger molecular size complexes with no evidence of lipoprotein dissociation into smaller fragments. 47 These alterations were speculated to arise from incorporation of some of the hydrophobic components of CrEL (e.g., glycerol-PEG-ricinoleate and fatty acid esters of PEG) into lipoproteins. 49 The components of CrEL that did not associate with lipoproteins were suggested to form large droplets (100-300 nm) exhibiting a high surface density of hydroxyl groups capable of assembling fluid phase C3bBb convertase.
COMPLEMENT ACTIVATION AND TUMOUR GROWTH
Complement has long been though to play a key role in fight against cancer. Contrary to this belief, intra-tumoural complement activation and C5a generation has now been shown to help tumour growth and progression and its molecular basis is discussed elsewhere. 6 50 The nature of the intra-tumoural complement activating trigger remains to be unraveled but the likely candidates include antitumour antibodies and tumour resident blood clots. This observation now raises an intriguing question as to whether intra-tumourally accumulated cancer nanomedicines (both conventional and trigger release systems) could also help tumour growth as they are well capable of activating complement. This also extends to approaches that generate thrombogenesis in tumour vasculature. Examples include thrombogenic immuno-phosphatidylserine liposomes targeted to vascular adhesion molecule 1 51 and the so-called nanoparticle approaches that target resident clotted plasma proteins and subsequently amplify their own homing through induction of more clot formation, 52 since kallikerin and thrombin can directly cleave C3 and C5 and generate anaphylatoxins5 (also discussed in Section 3).
CONCLUDING REMARKS
Activation of complement cascade by nanomedicines is of concern, as they can induce many inflammatory and lifethreatening conditions. Inhibition or modulation of complement activation with an array of complement protease inhibitors (e.g., Rhucin/recombinant human C1-INH), soluble complement regulators (e.g., recombinant truncated soluble form of CR1), therapeutic antibodies (e.g., humanized short-and long-acting monoclonal antibodies against C5), complement component inhibitors (e.g., peptidic C3 inhibitors such as Compstatin) and receptor antagonists (e.g., peptidic C5a receptor antagonist) has now been recognized as a promising therapeutic strategy of many diseases and disorders that include ischemic-reperfusion injury-related conditions, Alzheimer's disease, age-related macular degeneration, rheumatoid arthritis, cancer, sepsis and anaphylaxis and some are in late clinical trials. 53 Intravenous IgG also expresses scavenging function where it can neutralize C3a and C5a by low-affinity interaction with the constant domain of the F(ab). 2 54 Surely, such interventions must be introduced into the design and engineering of nanomedicines or at least combined with administration of clinical nanomedicines for better and safer patient management; these issues are discussed elsewhere. 3 50 In contrast, complement activation is perceived beneficial for adjuvanticity, which justifies the use of particulate agents like liposomes and other lipid-based assemblies as vaccine adjuvants. 3 
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